MindMed reports results for Q1 2022. Progress on clinical trials. Used $12.9 million cash in previous quarter. Cash balance of $120.5 million as of March 31, 2022.

Cybin Inc announces that it will take part in the NYSE’s “morning bell” ceremony for the May 18th trading session.

Awakn Life Sciences announces the appointment of noted expert in addictions psychiatry, Dr. Arun Dhandayudham as its new CMO.

A new partnership between the U.S. Veterans Administration and Delic Holdings is ushering in a new era for PTSD treatment in the U.S. military.

atai Life Sciences reports Q1 for 2022: clinical trials advancing and cash position of $335 million.

Numinus Wellness announces Health Canada approval of its application to use psilocybin-assisted therapy for treatment-resistant depression (TRD).

Red Light Holland announces successfully importing its psilocybin microdose packs from the Netherlands into Canada.

Delic Holdings announces that it will miss its deadline under Canadian Securities Law to file its audited financial results. As a results, a Management Cease Trade Order (MCTO) has been issued.

Mindset Pharma announces initial planning of its Phase 1 clinical trials for its first family of novel molecules.

Field Trip launches a telehealth version of its ketamine-assisted therapy, via a partnership with Nue Life Health.